Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

190
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
190
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

222
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
222
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

267
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
267
Fibronectins Connect Cells with ECM01:25

Fibronectins Connect Cells with ECM

3.4K
Fibronectin is an adhesive glycoprotein present in the extracellular matrix of embryogenic and adult tissue. These molecules primarily aid in regulating cell motility and attachment. A fibronectin molecule is composed of two identical polypeptide chains attached to each other by a pair of disulfide bonds at the C-terminal.
Both proteoglycans and collagen are attached to fibronectin proteins, which, in turn, are attached to integrin proteins. These integrin proteins interact with transmembrane...
3.4K
Protein Buffers in Blood Plasma and Cells01:20

Protein Buffers in Blood Plasma and Cells

3.7K
The human body utilizes protein buffer systems to maintain a stable pH. These systems capitalize on the dual role of amino acids, which can act as acids or bases by accepting or releasing hydrogen ions in response to pH changes. Protein buffer systems are particularly significant in the extracellular fluid (ECF) and intracellular fluid (ICF) of active cells, where structural and functional proteins provide substantial buffering capacity.
Certain amino acids can exist in a zwitterion state at a...
3.7K
Hepatic Portal System01:21

Hepatic Portal System

5.7K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transglutaminase-mediated fibronectin multimerization in lung endothelial matrix in response to TNF-alpha.

American journal of physiology. Lung cellular and molecular physiology·2000
Same author

Increased recycling of (alpha)5(beta)1 integrins by lung endothelial cells in response to tumor necrosis factor.

Journal of cell science·2000
Same author

Hepatic fibronectin matrix turnover in rats: involvement of the asialoglycoprotein receptor.

The American journal of physiology·1999
Same author

Lung matrix incorporation of plasma fibronectin reduces vascular permeability in postsurgical bacteremia.

The American journal of physiology·1999
Same author

Circulating cellular fibronectin may be a natural ligand for the hepatic asialoglycoprotein receptor: possible pathway for fibronectin deposition and turnover in the rat liver.

Hepatology (Baltimore, Md.)·1998
Same author

TNF-alpha-induced matrix Fn disruption and decreased endothelial integrity are independent of Fn proteolysis.

The American journal of physiology·1998
Same journal

Noncirrhotic portal hypertension: recent concepts.

Progress in liver diseases·1996
Same journal

Molecular advances in Wilson disease.

Progress in liver diseases·1996
Same journal

Hepatitis C virus genotypes: molecular basis and clinical significance.

Progress in liver diseases·1996
Same journal

Hepatocyte transplantation: progress toward liver repopulation.

Progress in liver diseases·1996
Same journal

Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular, and metabolic changes.

Progress in liver diseases·1996
Same journal

Oxidative stress and liver disease.

Progress in liver diseases·1996
See all related articles

Related Experiment Video

Updated: Jan 27, 2026

Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay
08:09

Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay

Published on: October 4, 2024

1.2K

Plasma fibronectin and hepatic Kupffer cell function

T M Saba

    Progress in Liver Diseases
    |January 1, 1982
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
    10:25

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

    Published on: February 19, 2019

    12.1K
    Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
    07:37

    Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

    Published on: November 17, 2017

    13.4K

    Related Experiment Videos

    Last Updated: Jan 27, 2026

    Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay
    08:09

    Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay

    Published on: October 4, 2024

    1.2K
    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
    10:25

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

    Published on: February 19, 2019

    12.1K
    Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
    07:37

    Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

    Published on: November 17, 2017

    13.4K